Ganglioneuroblastoma clinical trials
The registry lists 21 studies for Ganglioneuroblastoma across more than 10 countries. 10 are recruiting or about to start. 19 of them are mainly about Ganglioneuroblastoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Ganglioneuroblastoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Children's Oncology Group (7) · National Cancer Institute (NCI) (4) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (3) · Ilya Khaytin (1) · Mayo Clinic (1) · Seattle Children's Hospital (1) · Beijing Biotech (1) · Massachusetts General Hospital (1)
Who develops what
Save this setEvery programme with a company-led study here in the last two years, whatever its size: 1 programme from 1 company, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.
Stage, biomarker and line of therapy are not read yet: these programmes are in development here, not all in the same competitive position.
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
| Drug | Leading trial sponsor | Companies, last 5 years |
|---|---|---|
fludarabineRecent, limitedPhase 4 trial recordedEvidence
| Beijing Biotech18% of its industry studies | 11 study |
CyclophosphamideRecent, limitedPhase 4 trial recordedEvidence
| Hoffmann-La Roche13% of its industry studies | 11 study |
Programmes
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 1 programme — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (1)
Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
- 14 Mar 2027 est.EB-DTNB-NK · Beijing Biotech · Phase 2 main aimstudied with fludarabinestudied with CyclophosphamideNCT07502287 Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma — primary endpoint: Incidence of dose-limiting toxicities (DLTs) after first CARNK infusion, using protocol-defined DLT criteria. · 36 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. Phase 4 trial recorded: a phase 4 study exists somewhere; approval here is not checked. Not read yet: approvals and labels, exclusivity, licences, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Ganglioneuroblastoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Dinutuximab | 2 | 2 | 5 |
| Busulfan | 1 | 1 | 3 |
| Melphalan | 1 | 1 | 3 |
| Carboplatin | 1 | 2 | 2 |
| Irinotecan | 1 | 1 | 2 |
| Temozolomide | 1 | 1 | 2 |
| Iberdomide | 1 | 0 | 1 |
| Lorlatinib | 1 | 1 | 1 |
| Melphalan hydrochloride | 1 | 1 | 1 |
| Vincristine | 1 | 1 | 1 |
Drug classes tested here Alkylating agents 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2, phase 3 first
- Dec 2026Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma · Phase 3 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Mar 2027Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma · Beijing Biotech
Who these studies take
Of the 9 Ganglioneuroblastoma studies recruiting now, 2 (22%) set no upper age limit and 7 (78%) stop at 75 or younger. 9 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 9 (100%) | 9 (100%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 5 (56%) | 5 (56%) |
| 40 | 2 (22%) | 2 (22%) |
| 50 | 2 (22%) | 2 (22%) |
| 65 | 2 (22%) | 2 (22%) |
| 75 | 2 (22%) | 2 (22%) |
| 85 | 2 (22%) | 2 (22%) |
Across all 21 studies, recruiting or not: 81% stop at 75 or younger and 81% at 65; 100% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
Studies
Recruiting first, then most recently updated. Showing 21 of 21. search them.
- Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory NeuroblastomaRecruitingNCT07502287Phase 1/21 country
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecruitingNCT07437963Phase 1/21 country
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruitingNCT06172296Phase 35 countries
- International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARERecruitingNCT030880201 country
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingNCT03126916Phase 33 countries
- Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaRecruitingNCT07375563Phase 31 country
- Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic TumorsNot yet recruitingNCT067985321 country
- SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic TumoursRecruitingNCT05192980Not applicable4 countries
- Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors StratificationRecruitingNCT062967321 country
- Induction Chemoimmunotherapy for Patients With High-risk NeuroblastomaRecruitingNCT06071897Phase 31 country
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk NeuroblastomaActive, not recruitingNCT02176967Phase 36 countries
- Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk NeuroblastomaWithdrawnNCT06858501Phase 2
- Phase II Study of Proton Radiation Therapy for NeuroblastomaActive, not recruitingNCT02112617Not applicable1 country
- Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or GanglioneuroblastomaCompletedNCT009042418 countries
- Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedNCT03786783Phase 23 countries
- Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01Active, not recruitingNCT02311621Phase 11 country
- An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine TumorsActive, not recruitingNCT04040088Early Phase 11 country
- Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With IsotretinoinCompletedNCT01175356Phase 11 country
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Active, not recruitingNCT04385277Phase 24 countries
- Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedNCT01798004Phase 14 countries
- Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed NeuroblastomaCompletedNCT01767194Phase 25 countries